The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care for ovarian cancer; however, treatment is moving toward a targeted approach with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inhibitors: AstraZeneca /Merck Sharp & Dohme’s Lynparza, Clovis Oncology’s Rubraca, and GlaxoSmithKline/Tesaro’s Zejula. Multiple combination therapies using immune checkpoint inhibitors are in late-phase development for ovarian cancer, and we anticipate that this drug class will significantly change the indication’s treatment paradigm.

Questions Answered:

  • What is the size of the drug-treatable ovarian cancer population, and how will the drug-treatment rates change over time?
  • What is the current state of treatment in ovarian cancer? Which drugs are the most important? What are interviewed experts’ insights on current treatment options? What are the main unmet needs in ovarian cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer market? What notable therapies are progressing in early-phase trials?
  • What is the expected impact of the approvals of Roche / Genentech /Chugai’s Tecentriq, GlaxoSmithKline / Tesaro’s dostarlimab, AstraZeneca’s Imfinzi, Bristol-Myers Squibb / Ono Pharmaceutical’s Opdivo, and Merck Sharp & Dohme’s Keytruda on the ovarian cancer market? What competition will other drug classes present to immune checkpoint inhibitors?
  • What are the drivers and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: More than 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.

Key companies: Roche/Genentech, GlaxoSmithKline/Tesaro, Clovis Oncology, AstraZeneca, AbbVie, Merck KGaA, Pfizer, Bristol-Myers Squibb, Merck & Co., ImmunoGen, Sotio, VBL Therapeutics, Novartis.

Key drugs: Avastin (bevacizumab), Lynparza (olaparib), Zejula (niraparib), Rubraca (rucaparib), Talzenna (talazoparib), Opdivo (nivolumab), Bavencio (avelumab), Tecentriq (atezolizumab), Imfinzi (durvalumab), Keytruda (pembrolizumab), Mekinist (trametinib), dostarlimab, mirvetuximab soravtansine, cediranib, ofranergene obadenovec, DCVAC/OvCa, mirvetuximab soravtansine.

Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).

Population segments in market forecast: Early-stage first line, advanced-stage first line, second-line platinum-sensitive, second-line platinum-resistant and -refractory, third-line platinum-sensitive, third-line platinum-resistant and -refractory, and fourth and subsequent lines.

Market forecast features: Ten-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2028, segmented by brands/generics and epidemiological subpopulations.

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Grace Mitchell, M.Res; Alison Isherwood, MSc, MRes, PhD

is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a B.Sc. in Biomedical Science from the University of Reading.

Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.